Clinical performance of the APTIMA® HPV Assay for the detection of high-risk HPV and high-grade cervical lesions

Journal of Clinical Virology

Volumn 45, Issue SUPPL. 1, 2009, Pages

  Dockter, Janel ^a   Schroder, Astrid ^a   Hill, Craig ^a   Guzenski, Leah ^a   Monsonego, Joseph ^b   Giachetti, Cristina ^a  

^a Gen Probe Incorporated   (United States)

^b European Institute of Cervix Federation Mutualiste   (France)

Author keywords

Clinical sensitivity; Clinical specificity; HPV; mRNA

Indexed keywords

ARTICLE; CANCER RISK; CANCER SCREENING; COLPOSCOPY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NUCLEIC ACID AMPLIFICATION; PAPANICOLAOU TEST; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; REAGENT KITS, DIAGNOSTIC; RNA, MESSENGER; RNA, VIRAL; SENSITIVITY AND SPECIFICITY;

EID: 67949085305     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6532(09)70009-5     Document Type: Article

References (43)

1. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human Papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 (1999) 12
2. Schiffman M.H., Bauer H.M., Hoover R.N., Glass A.G., Cadell D.M., Rush B.B., et al. Epidemiologic evidence showing that human Papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 85 (1993) 958-964
3. Muñoz N., Bosch F.X., de Sanjosé S., Herrero R., Castellsagué X., Shah K.V., et al., International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 (2003) 518-527
4. Kjaer S.K., van den Brule A.J., Paull G., Svare E.I., Sherman M.E., Thomsen B.L., et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 325 7364 (2002) 572-579
5. Clifford G.M., Gallus S., Herrero R., Muñoz N., Snijders P.J., Vaccarella S., et al., IARC HPV Prevalence Surveys Study Group. Worldwide distribution of human papillomavirus types in cytologically normal women in the Internation Agency for research on Cancer HPV prevalence surveys: pooled analysis. Lancet 366 (2005) 991-998
6. Clifford G.M., Rana R.K., Franceschi S., Smith J.S., Gough G., and Pimenta J.M. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 14 (2005) 1157-1164
7. Wright Jr. T.C., Massad L.S., Dunton C.J., Spitzer M., Wilkinson E.J., and Solomon D. 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 197 (2007) 346-355
8. Cuzick J., Clavel C., Petry K.U., Meijer C.J., Hoyer H., Ratnam S., et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 119 (2006) 1095-1101
9. Wright Jr. T.C., Schiffman M., Solomon D., Cox J.T., Garcia F., and Goldie S. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 103 (2004) 304-309
10. Naucler P., Ryd W., Törnberg S., Strand A., Wadell G., Elfgren K., et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 357 (2007) 1589-1597
11. Koliopoulos G., Arbyn M., Martin-Hirsch P., Kyrgiou M., Prendiville W., and Paraskevaidis E. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of nonrandomized studies. Gynecol Oncol 104 (2007) 232-246
12. Petry K.U., Menton S., Menton M., van Loenen-Frosch F., de Carvalho Gomes H., and Holz B. Inclusion of HPV testing in routine cercical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer 88 (2003) 1570-1577
13. Castle P.E., Solomon D., Wheeler C.M., Gravitt P.E., Wacholder S., and Schiffman M. Human papillomavirus genotype specificity of Hybrid Capture 2. J Clin Microbiol 48 (2008) 2595-2604
14. Digene hc2 Hybrid Capture® 2 High-Risk HPV DNA Test® [package insert]. Digene Corp., Gaithersburg, MD, USA; 2007.
15. Mo L.Z., Monnier-Benoit S., Kantelip B., Petitjean A., Riethmuller D., Prétet J.L., et al. Comparison of AMPLICOR and Hybrid Capture II assays for high-risk HPV detection in normal and abnormal liquid-based cytology: use of INNO-LiPA Genotyping assay to screen the discordant results. J Clin Virol 41 (2008) 104-110
16. Carozzi F., Bisanzi S., Sani C., Zappa M., Cecchini S., Ciatto S., et al. Agreement between the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease. J Clin Microbiol 45 (2007) 364-369
17. Halfon P., Trepo E., Antoniotti G., Bernot C., Cart-Lamy P., Khiri H., et al., RBML (Réseau de Biologie Moléculaire Libérale). Prospective evaluation of the Hybrid Capture 2 and AMPLICOR human papillomavirus (HPV) tests for detection of 13 high-risk HPV genotypes in atypical squamous cells of uncertain significance. J Clin Microbiol 45 (2007) 313-316
18. Monsonego J., Bohbot J.M., Pollini G., Krawec C., Vincent C., Merignargues I., et al. Performance of the ROCHE AMPLICOR Human Papillomavirus (HPV) test in detection of cervical intraepithelial neoplasia (CIN) in management of women with abnormal PAP smear. Gynecol Oncol 99 (2005) 160-168
19. Stevens M.P., Garland S.M., Rudland E., Tan J., Quinn M.A., and Tabrizi S.N. Comparison of the Digene Hybrid Capture 2 assay and Roche AMPLICOR and LINEAR ARRAY human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results. J Clin Microbiol 45 (2007) 2130-2137
20. De Francesco M.A., Gargiulo F., Schreiber C., Ciravolo G., Salinaro F., and Manca N. Comparison of the AMPLICOR human papillomavirus test and the Hybrid Capture 2 assay for detection of high-risk human papillomavirus in women with abnormal PAP smear. J Virol Methods 147 (2008) 10-17
21. Wahlström C., Iftner T., Dillner J., Dillner L., and Swedescreen study group. Population-based study of screening test performance indices of three human papillomavirus DNA tests. J Med Virol 79 (2007) 1169-1175
22. Monsonego J., Pollini G., Evrard M.J., Sednaoui P., Monfort L., Zerat L., et al. Detection of human papillomavirus genotypes among high-risk women: a comparison of Hybrid Capture and Linear Array tests. Sex Transm Dis 35 5 (2008) 521-527
23. Monsonego J., Pollini G., Evrard M.J., Sednaoui P., Monfort L., Quinzat D., et al. Linear array genotyping and Hybrid Capture II assay in detecting human papillomavirus genotypes in women referred for colposcopy due to abnormal Papanicolaou smear. Int J STD AIDS 19 6 (2008) 385-392
24. Wong A.K., Chan R.C., Nichols W.S., and Bose S. Invader human papillomavirus (HPV) type 16 and 18 assays as adjuncts to HPV screening of cervical papanicolaou smears with atypical squamous cells of undetermined significance. Cancer 115 4 (2009) 823-832
25. Ginocchio C.C., Barth D., and Zhang F. Comparison of the Third Wave Invader human papillomavirus (HPV) assay and the digene HPV Hybrid Capture 2 assay for detection of high-risk HPV DNA. J Clin Microbiol 46 5 (2008) 1641-1646
26. Johnson L.R., Starkey C.R., Palmer J., Taylor J., Stout S., Holt S., et al. A comparison of two methods to determine the presence of high-risk HPV cervical infections. Am J Clin Pathol 130 3 (2008) 401-408
27. Meijer C.J., van den Brule A.J., Snijders P.J., Helmerhorst T., Kenemans P., and Walboomers J.M. Detection of human papillomavirus in cervical scrapes by the polymerase chain reaction in relation to cytology: possible implications for cervical cancer screening. IARC Sci Publ 119 (1992) 271-281
28. Walboomers J.M.M., De Roda Husman A.M., Snijders P.J.F., Stel H.V., Risse E., Helmelhorst T.J.M., et al. Detection of genital human papillomavirus infections. Critical review of methods and prevalence studies in relation to cervical cancer. In: Stern P.L., and Stanley M.A. (Eds). Human papillomavirus and cervical cancer. Biology and immunology (1994), Oxford University Press, Oxford 41-71
29. Sotlar K., Stubner A., Diemer D., Menton S., Menton M., Dietz K., et al. Detection of high-risk human papillomavirus E6 and E7 oncogene transcripts in cervical scrapes by nested RT-polymerase chain reaction. J Med Virol 74 (2004) 107-116
30. Lie A.K., and Dristensen G. Human Papillomavirus E6/E7 mRNA testing as a predictive marker for cervical carcinoma. Expert Rev Mol Diagn 8 (2008) 405-415
31. Burd E.M. Human papillomavirus and cervical cancer. Clin Microbiol Rev 16 (2003) 1-17
32. Cuschieri K.S., Whitley M.J., and Cubie H.A. Human papillomavirus type specific DNA and RNA persistence implications for cervical disease progression and monitoring. J Med Virol 73 (2004) 65-70
33. Czegledy J., Losif C., Hansson B.G., Evander M., Gergely L., and Wadell G. Can a test for E6/E7 transcripts of human papillomavirus type 16 serve as a diagnostic tool for the detection of micrometastasis in cervical cancer?. Int J Cancer 64 (1995) 211-215
34. Cuschieri K., and Wentzensen N. Human Papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 17 (2008) 2536-2545
35. Castle P.E., Dockter J., Giachetti C., Garcia F.A., McCormick M.K., Mitchell A.L., et al. A cross-sectional study of a prototype carcinogenic human Papillomavirus E6/E7 mRNA assay for detection of cervical precancer and cancer. Clin Cancer Res 13 (2007) 2599-2605
36. Szarewski A., Ambroisine L., Cadman L., Austin J., Ho L., Terry G., et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev 17 (2008) 3033-3042
37. APTIMA® HPV Assay [package insert]. Gen-Probe Incorporated, San Diego, CA, USA; 2008.
38. LINEAR ARRAY HPV Genotyping Test [package insert]. Roche Molecular Diagnostics, Pleasanton, CA, USA; 2009.
39. Wilson E.B. Probable inference, the law of succession, and statistical inference. J Am Statist Assoc 22 (1927) 209-212
40. McNemar Q. Note on the sampling error of the difference between correlated proportions or percentages. Psychometrika 12 (1947) 153-157
41. van Doorn L.J., Quint W., Kleter B., Molijn A., Colau B., Martin M.T., et al. Genotyping of human papillomavirus in liquid cytology cervical specimens by the PGMY line blot assay and the SPF(10) line probe assay. J Clin Microbiol 40 (2002) 979-983
42. van Hamont D., van Ham M.A., Bakkers J.M., Massuger L.F., and Melchers W.J. Evaluation of the SPF10-INNO LiPA human papillomavirus (HPV) genotyping test and the Roche linear array HPV genotyping test. J Clin Microbiol 44 (2006) 3122-3129
43. de Villiers E.M., Fauquet C., Broker T.R., Bernard H.U., and zur Hausen H. Classification of papillomaviruses. Virology 324 (2004) 17-27